Pilot study: Alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma

International Journal of Molecular Sciences

Volumn 12, Issue 12, 2011, Pages 8489-8501

  Fan, Dong Mei ^a,b   Shi, Hui Rong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

DLC1; Gynecologic cancers; Ovarian carcinoma; p FAK; Prognosis

Indexed keywords

FOCAL ADHESION KINASE 1; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; DLC1 PROTEIN, HUMAN; PTK2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DELETION IN LIVER CANCER GENE; ENZYME PHOSPHORYLATION; EPITHELIAL OVARY CARCINOMA; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PILOT STUDY; PROGNOSIS; TUMOR SUPPRESSOR GENE; CARCINOMA; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PHOSPHORYLATION;

ADULT; AGED; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; FOCAL ADHESION KINASE 1; GTPASE-ACTIVATING PROTEINS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PHOSPHORYLATION; PILOT PROJECTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84055176318     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12128489     Document Type: Article

References (39)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics. CA Cancer J. Clin. 2008, 58, 71-96.
2. Tung, C.S.; Wong, K.K.; Mok, S.C. Biomarker discovery in ovarian cancer. Women's Health 2008, 4, 27-40.
3. Permuth-Wey, J.; Sellers, T.A. Epidemiology of ovarian cancer. Methods Mol. Biol. 2009, 472, 413-437.
4. Martin, L.P.; Schilder, R.J. Management of recurrent ovarian carcinoma: Current status and future directions. Semin. Oncol. 2009, 36, 112-125.
5. Pectasides, D.; Papaxoinis, G.; Fountzilas, G.; Aravantinos, G.; Bamias, A.; Pavlidis, N.; Kalofonos, H.P.; Timotheadou, E.; Samantas, E.; Briasoulis E.; et al. Hellenic Cooperative Oncology Group. Epithelial ovarian cancer in Greece: A retrospective study of 1791 patients by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Res. 2009, 29, 745-751.
6. Larsen, E.; Blaakaer, J. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance? Acta Obstet. Gynecol. Scand. 2009, 88, 373-377.
7. Denkert, C.; Budczies, J.; Darb-Esfahani, S.; Györffy, B.; Sehouli, J.; Könsgen, D.; Zeillinger, R.; Weichert, W.; Noske, A.; Buckendahl A.C.; et al. A prognostic gene expression index in ovarian cancer-validation across different independent data sets. J. Pathol. 2009, 218, 273-280.
8. Yuan, B.Z.; Miller, M.J.; Keck, C.L.; Zimonjic, D.B.; Thorgeirsson, S.S.; Popescu, N.C. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998, 58, 2196-2199.
9. Ng, I.O.; Liang, Z.D.; Cao, L.; Lee, T.K. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res. 2000, 60, 6581-6584.
10. Yuan, B.Z.; Durkin, M.E.; Popescu, N.C. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet. Cytogenet. 2003, 140, 113-117.
11. Yuan, B.Z.; Zhou, X.; Durkin, M.E.; Zimonjic, D.B.; Gumundsdottir, K.; Eyfjord, J.E.; Thorgeirsson, S.S.; Popescu, N.C. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene 2003, 22, 445-450.
12. Kim, T.Y.; Jong, H.S.; Song, S.H.; Dimtchev, A.; Jeong, S.J.; Lee, J.W.; Kim, T.Y.; Kim, N.K.; Jung, M.; Bang, Y.J. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 2003, 22, 3943-3951.
13. Yuan, B.Z.; Jefferson, A.M.; Baldwin, K.T.; Thorgeirsson, S.S.; Popescu, N.C.; Reynolds, S.H. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004, 23, 1405-1411.
14. Hall, A., Rho GT Pases and the actin cytoskeleton. Science 1998, 279, 509-514.
15. Durkin, M.E.; Yuan, B.Z.; Zhou, X.; Zimonjic, D.B.; Lowy, D.R.; Thorgeirsson, S.S.; Popescu, N.C. DLC-1, a Rho GTPase-activating protein and tumour suppressor. J. Cell. Mol. Med. 2007, 11, 1185-1207.
16. Kim, T.Y.; Lee, J.W.; Kim, H.P.; Jong, H.S.; Kim, T.Y.; Jung, M.; Bang, Y.J. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2007, 355, 72-77.
17. Wong, C.M.; Yam, J.W.; Ching, Y.P.; Yau, T.O.; Leung, T.H.; Jin, D.Y.; Ng, I.O. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res. 2005, 65, 8861-8868.
18. Goodison, S.; Yuan, J.; Sloan, D.; Kim, R.; Li, C.; Popescu, N.C.; Urquidi, V. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 2005, 65, 6042-6053.
19. Luo, Y.; Liang, F.; Zhang, Z.Y. PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry 2009, 48, 1838-1846.
20. Pylayeva, Y.; Gillen, K.M.; Gerald, W.; Beggs, H.E.; Reichardt, L.F.; Giancotti, F.G. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J. Clin. Invest. 2009, 119, 252-266.
21. Cornillon, J.; Campos, L.; Guyotat, D. Focal adhesion kinase (FAK), a multifunctional protein. Med. Sci. (Paris) 2003, 19, 743-752.
22. Watari, H.; Xiong, Y.; Hassan, M.K.; Sakuragi, N. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecologic Oncology 2009, 112, 229-234.
23. Ullmannova-Benson, V.; Guan, M.; Zhou, X.; Tripathi, V.; Yang, X.Y.; Zimonjic, D.B.; Popescu, N.C. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia 2009, 23, 383-390.
24. Wong, C.C.; Wong, C.M.; Ko, F.C.; Chan, L.K.; Ching, Y.P.; Yam, J.W.; Ng, I.O. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One 2008, 3, doi:10.1371/journal.pone.0002779.g008.
25. Pils, D.; Horak, P.; Gleiss, A.; Sax, C.; Fabjani, G.; Moebus, V.J.; Zielinski, C.; Reinthaller, A.; Zeillinger, R.; Krainer, M. Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer 2005, 104, 2417-2429.
26. Amirghofran, Z.; Jalali, S.A.; Hosseini, S.V.; Vasei, M.; Sabayan, B.; Ghaderi, A. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: Soluble forms in relation to tumor tissue expression and metastasis. J. Gastrointest. Cancer 2008, 39, 73-78.
27. Inose, T.; Kato, H.; Kimura, H.; Faried, A.; Tanaka, N.; Sakai, M.; Sano, A.; Sohda, M.; Nakajima, M.; Fukai, Y.; et al. Correlation between connexin 26 expression and poor prognosis of esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2009, 16, 1704-1710.
28. Hsu, P.I.; Hsieh, H.L.; Lee, J.; Lin, L.F.; Chen, H.C.; Lu, P.J.; Hsiao, M. Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann. Surg. Oncol. 2009, 16, 1686-1694.
29. Fan, T.; Zhao, Q.; Chen, J.J.; Chen, W.T.; Pearl, M.L. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol. Oncol. 2009, 112, 185-191.
30. Shield, K.; Ackland, M.L.; Ahmed, N.; Rice, G.E. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol. Oncol. 2009, 113, 143-148.
31. Zhang, T.; Zheng, J.; Liu, C.; Lu, Y. Expression of DLC-1 in clear cell renal cell carcinoma: Prognostic significance for progression and metastasis. Urol. Int. 2009, 82, 380-387.
32. Liao, Y.C.; Si, L.; deVere White, R.W.; Lo, S.H. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J. Cell Biol. 2007, 176, 43-49.
33. Yam, J.W.; Ko, F.C.; Chan, C.Y.; Jin, D.Y.; Ng, I.O. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 2006, 66, 8367-8372.
34. Kawai, K.; Kitamura, S.Y.; Maehira, K.; Seike, J.; Yagisawa, H. START-GAP1/DLC1 is localized in focal adhesions through interaction with the PTB domain of tensin2. Adv. Enzyme Regul. 2010, 50, 202-215.
35. Cho, K.R.; Shih, I.M. Ovarian cancer. Ann. Rev. Pathol. 2009, 4, 287-313.
36. Lund, B.; Williamson, P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann. Oncol. 1991, 2, 281-287.
37. Vergote, I. Prognostic factors in stage I ovarian carcinoma. Verh. K. Acad. Geneeskd. Belg. 2001, 63, 257-271; discussion 272-276.
38. Villedieu, M.; Deslandes, E.; Duval, M.; Héron, J.F.; Gauduchon, P.; Poulain, L. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol. Oncol. 2006, 101, 507-519.
39. Duxbury, M.S.; Ito, H.; Benoit, E.; Zinner, M.J.; Ashley, S.W.; Whang, E.E. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem. Biophys. Res. Commun. 2003, 311, 786-792.